<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int Urogynecol J</journal-id><journal-id journal-id-type="iso-abbrev">Int Urogynecol J</journal-id><journal-title-group><journal-title>International Urogynecology Journal</journal-title></journal-title-group><issn pub-type="ppub">0937-3462</issn><issn pub-type="epub">1433-3023</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39509058</article-id><article-id pub-id-type="pmc">PMC11785600</article-id>
<article-id pub-id-type="publisher-id">5960</article-id><article-id pub-id-type="doi">10.1007/s00192-024-05960-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Predictive Factors for Clean Intermittent Catheterization after Intravesical OnabotulinumtoxinA Injections in Women with Overactive Bladder: a Danish Retrospective Cohort Study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>El Issaoui</surname><given-names>Meryam</given-names></name><address><email>meryam.el.issaoui.01@regionh.dk</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Elissaoui</surname><given-names>Sophia</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Elmelund</surname><given-names>Marlene</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Klarskov</surname><given-names>Niels</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/051dzw862</institution-id><institution-id institution-id-type="GRID">grid.411646.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 0646 7402</institution-id><institution>Department of Obstetrics and Gynecology, </institution><institution>Herlev and Gentofte University Hospital, </institution></institution-wrap>Borgmester Ib Juuls Vej 1, 16. Etage, 2730 Herlev, Denmark </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/035b05819</institution-id><institution-id institution-id-type="GRID">grid.5254.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 0674 042X</institution-id><institution>Department of Clinical Medicine, </institution><institution>University of Copenhagen, </institution></institution-wrap>Copenhagen, Denmark </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00edrn755</institution-id><institution-id institution-id-type="GRID">grid.411905.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 0646 8202</institution-id><institution>Department of Gynecology and Obstetrics, </institution><institution>Amager and Hvidovre Hospital, </institution></institution-wrap>Hvidovre, Denmark </aff></contrib-group><pub-date pub-type="epub"><day>7</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>7</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>36</volume><issue>1</issue><fpage>107</fpage><lpage>115</lpage><history><date date-type="received"><day>24</day><month>5</month><year>2024</year></date><date date-type="accepted"><day>19</day><month>7</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Introduction and Hypothesis</title><p id="Par1">We aimed to evaluate the clean intermittent catheterization (CIC) rate in women undergoing their first OnabotulinumtoxinA (BTX-A) treatment and to investigate factors predictive of initiating CIC.</p></sec><sec><title>Methods</title><p id="Par2">This was a retrospective cohort of women, who had their first BTX-A treatment for symptoms of overactive bladder (OAB) syndrome, with a pretreatment urodynamic study (UDS). We reviewed demographic, medical and gynecological history, UDS, pretreatment bladder diaries, objective examinations, BTX-A treatment details, and post-void residual (PVR) reports in the electronic medical record. Botox&#x000ae; Allergan 100 International Units were injected into the detrusor at 10&#x02013;20 sites. Statistical analyses included univariate and multivariate logistic regression analyses.</p></sec><sec><title>Results</title><p id="Par3">We included 397 women. Median age was 68 (Q1&#x02013;Q3: 54&#x02013;76) years. CIC rate was 8.6% (<italic>n</italic>&#x02009;=&#x02009;34) following the first BTX-A treatment. Urgency urinary incontinence (UUI) reduced the risk of undergoing CIC (OR 0.30, 95% CI 0.09&#x02013;0.97). A bladder capacity of 500&#x000a0;ml or greater in the bladder diary increased the risk of CIC (OR 2.46, 95% CI 1.06&#x02013;5.70), whereas reported leakages were associated with a decreased risk of CIC (OR 0.24, 95% CI 0.10&#x02013;0.57). Multivariate logistic regression analysis showed that anterior colporrhaphy (OR 3.71, 95% CI 1.52&#x02013;9.06) and 10-ml increments in median maximum cystometric capacity (OR 1.03, 95% CI 1.00&#x02013;1.06) predicted CIC, whereas UUI was a protective factor for CIC (OR 0.23, 95% CI 0.07&#x02013;0.79).</p></sec><sec><title>Conclusions</title><p id="Par4">A history of anterior colporrhaphy, large bladder capacity, and absence of incontinence episodes in bladder diary or UDS were risk factors for CIC after the first BTX-A treatment.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Clean intermittent catheterization</kwd><kwd>OnabotulinumtoxinA</kwd><kwd>Overactive bladder syndrome</kwd><kwd>Post-void residuals</kwd><kwd>Urgency urinary incontinence</kwd><kwd>Urinary retention</kwd></kwd-group><funding-group><award-group><funding-source><institution>Copenhagen University</institution></funding-source></award-group><open-access><p>Open access funding provided by Copenhagen University</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The International Urogynecological Association 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par5">Intradetrusor OnabotulinumtoxinA (BTX-A) injections are a well-established third-line treatment for overactive bladder (OAB) syndrome. BTX-A treatment is effective for patients with OAB syndrome and urgency urinary incontinence (UUI) who have not been adequately managed by prior anticholinergic and &#x000df;3-adrenoceptor agonist therapy. This effect has been demonstrated in large randomized clinical trials (RCTs) [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR4">4</xref>]. Nearly 1,000 BTX-A treatments are performed annually at our tertiary Urogynecology Clinic, and numbers are increasing.</p><p id="Par6">Common adverse effects of BTX-A treatment are urinary tract infections (UTIs) and urinary retention. A recent meta-analysis found a significantly increased risk of urinary retention, with a relative risk (RR) of 8.89 (95% CI: 4.39&#x02013;17.6), following BTX-A treatment compared with placebo [<xref ref-type="bibr" rid="CR1">1</xref>]. A previous review of adverse events following BTX-A treatment reported clean intermittent catheterization (CIC) rates between 6.2 and 43.8% [<xref ref-type="bibr" rid="CR5">5</xref>]. Existing literature is heterogeneous with smaller populations and lacks a standardized definition for initiating CIC. Further elucidation is needed to identify risk factors for urinary retention and CIC after BTX-A treatment [<xref ref-type="bibr" rid="CR5">5</xref>]. CIC is a procedure associated with discomfort and the risk of UTI [<xref ref-type="bibr" rid="CR6">6</xref>]. In a clinical setting, it would be important to predict the risk of CIC from the patients&#x02019; medical and urogynecological history and examination, including urodynamic studies (UDS). Predicting CIC associated with BTX-A would improve patient selection, help to manage patient expectations, and aid in patient counseling and referral for BTX-A treatment. Some patients opt out of BTX-A treatments because of the risk of urinary retention [<xref ref-type="bibr" rid="CR7">7</xref>]. Therefore, the ability to provide more specific counseling is of clinical interest.</p><p id="Par7">In this study, we aimed to evaluate the CIC rate in women undergoing their first intradetrusor BTX-A treatment and to investigate factors predictive of initiating CIC.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Materials and Methods</title><p id="Par8">Our retrospective cohort study was approved by the Capital Region&#x02019;s Knowledge Center for Data Reviews (ID: R-21013125). Data extraction of this cohort of women, who had their first BTX-A treatment at the Department of Gynecology and Obstetrics between January 2015 and December 2020, was from the electronic medical journal system Epic Systems. Patient data, including demographics, medical and gynecological history, UDS, pretreatment bladder diary, objective examinations, information on BTX-A treatments, and information on post-void residual (PVR) reporting were reviewed in the medical record. All collected data were stored in the online database Research Electronic Data Capture (REDCap).</p><sec id="Sec3"><title>Study Population</title><p id="Par9">Women older than 18&#x000a0;years, who had their first BTX-A treatment in our Urogynecology Clinic between January 2015 and December 2020, were identified. Referral for BTX-A treatment was based on complaints of urgency or UUI. In our clinical practice,&#x000a0;patients may receive BTX-A treatment if clinically indicated, irrespective of UDS-confirmed detrusor overactivity.</p><p id="Par10">Inclusion criteria were a pretreatment UDS available for assessment in the medical record.</p><p id="Par11">Most patients receiving BTX-A treatment in our clinic have undergone UDS. Patients in this study were included based on the availability of UDS records. Women with a PVR requiring CIC before the first BTX-A treatment were excluded.</p></sec><sec id="Sec4"><title>OnabotulinumtoxinA Treatment</title><p id="Par12">Patients were treated with OnabotulinumtoxinA (BTX-A), Botox&#x000ae; Allergan. BTX-A was injected into the detrusor at 10&#x02013;20 sites under cystoscopic guidance, sparing the trigone. Treatments were administered by urogynecologists or certified nurses, either in an operating theatre or our outpatient clinic, depending on the need for sedation during injections. Perioperative or prophylactic antibiotics were not routinely administered. Antibiotics were prescribed if the clinician identified an increased risk of post-treatment UTI or observed perioperative signs or symptoms of a UTI.</p></sec><sec id="Sec5"><title>Bladder Diary and Urodynamic Studies</title><p id="Par13">Patients referred to our clinic usually fill out a 2-day bladder diary. Available pretreatment bladder diary parameters were assessed by calculating the average of the 2-day results. Parameters from the bladder diaries included: fluid intake, number of voids, void volumes, and leakage episodes.</p><p id="Par14">Post-void residual from free flow was assessed by ultrasound during gynecological examination or by bladder scan.</p><p id="Par15">Urodynamic studies were performed by a certified nurse and followed the International Continence Society&#x02019;s (ICS) recommendations. The Medical Measurement Systems (MMSl Solar System), was used with the following equipment: Dual Lumen Catheters 7F (reference number DLC-7D), Laborie Abdominal Pressure Catheter size 9F (reference number RPC-9), Meritrans DTXPlus transducers (Reference number 682018), MMS filling tube for Nexam (reference number OBS 275/C (33252)), and Laborie Pressure Transmission Tubing-Clear (Reference number PTTA-C).</p><p id="Par16">In our clinic, UDS were initially performed with women seated, followed by a standing-position measurement if indicated by the initial test results. Filling cystometry was conducted using tempered physiological saline 0.9% at a filling rate of 50&#x000a0;ml per minute. During the filling phase, the following parameters were measured: bladder sensation, first desire to void, cystometric detrusor overactivity, volume at first detrusor contraction, detrusor overactivity incontinence, maximum detrusor pressure during filling, maximum cystometric capacity (MCC), and urodynamic stress incontinence. PVR was measured using a sterile single-use catheter. UDS results presented in this study were based on a renewed analysis of UDS by the authors.</p></sec><sec id="Sec6"><title>Post-Void Residual Reporting</title><p id="Par17">Patients undergoing BTX-A treatments are routinely informed to contact our outpatient clinic if they experience adverse effects, primarily bladder-emptying problems. Some patients contact our clinic regarding UTI symptoms, whereas others consult their general practitioner for UTI assessment and treatment. Follow-up assessments of PVR are scheduled for selected patients based on the health care provider's evaluation.</p><p id="Par18">For the outcome analysis, patients were included in the CIC group if post-treatment PVR required clean intermittent catheterization (CIC) and in the non-CIC group otherwise.</p><p id="Par19">Our clinical guideline defines significant PVR and indication for post-treatment CIC as PVR greater than 200&#x000a0;ml, with symptoms such as incomplete bladder emptying, suprapubic pain, UTIs, or urgency, or asymptomatic PVR greater than 350&#x000a0;ml. Patients with PVR between 200 and 350&#x000a0;ml are offered expectant treatment with follow-up assessments as needed.</p></sec><sec id="Sec7"><title>Statistical Analysis</title><p id="Par20">Data were analyzed in R Studio, version 2022.07.1. Results were reported as medians with interquartile ranges (Q1&#x02013;Q3) and percentages. Differences in continuous variables between the two outcome groups were assessed using the Wilcoxon rank sum test. Categorical variables were compared using Pearson&#x02019;s Chi-squared test or Fisher&#x02019;s exact test. We conducted univariate and multivariate logistic regression analyses to examine the odds of CIC. All statistical assessments were considered significant at a level of <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05.</p></sec></sec><sec id="Sec8" sec-type="results"><title>Results</title><p id="Par21">We included 400 women who had pretreatment UDS. Of these, 3 were excluded at baseline because they did CIC in the pretreatment period. In total, 397 were included in the analyses. Overall median age at first BTX-A treatment was 68 (Q1&#x02013;Q3: 54&#x02013;76) years.</p><p id="Par22">There were no significant differences in baseline demographics and characteristics between the CIC group and the non-CIC group (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Perioperative antibiotics were administered to 46 of the women (11.6%) and were associated with an increased risk of CIC (OR 3.17, 95% CI 1.38&#x02013;7.31). In the post-treatment period, 41 women (8.5%) had UTIs requiring antibiotic treatment, and among them, 19 (46.3%) underwent CIC. UTI was associated with an increased risk of CIC (OR 19.6, 95% CI 8.80&#x02013;43.81).
<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Baseline characteristics in the clean intermittent catheterization (CIC) group and the non-CIC group</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Variable</th><th align="left"><italic>N</italic></th><th align="left">Missing (<italic>n</italic>)</th><th align="left">CIC group</th><th align="left">Non-CIC group</th><th align="left"><italic>p</italic> value</th></tr></thead><tbody><tr><td align="left">Age, median (Q1&#x02013;Q3)</td><td align="left">397</td><td align="left">0</td><td align="left">66.5 (49.3&#x02013;73.8)</td><td align="left">69 (55&#x02013;76)</td><td align="left">0.353*</td></tr><tr><td align="left">BMI (kg/m<sup>2</sup>), median (Q1&#x02013;Q3)</td><td align="left">397</td><td align="left">0</td><td align="left">27.0 (24.8&#x02013;30.5)</td><td align="left">28.4 (24.6&#x02013;32.7)</td><td align="left">0.169*</td></tr><tr><td align="left">Chronic diseases, <italic>n</italic> (%)</td><td align="left">334</td><td align="left">0</td><td align="left">28 (82.4)</td><td align="left">306 (84.3)</td><td align="left">0.767**</td></tr><tr><td align="left">Diabetes, <italic>n</italic> (%)</td><td align="left">57</td><td align="left">0</td><td align="left">3 (8.8)</td><td align="left">54 (14.9)</td><td align="left">0.448***</td></tr><tr><td align="left">Cardiovascular diseases, <italic>n</italic> (%)</td><td align="left">204</td><td align="left">0</td><td align="left">15 (44.1)</td><td align="left">189 (52.1)</td><td align="left">0.640**</td></tr><tr><td align="left">Obesity, <italic>n</italic> (%)</td><td align="left">161</td><td align="left">0</td><td align="left">11 (32.4)</td><td align="left">150 (41.3)</td><td align="left">0.403**</td></tr><tr><td align="left">CNS diseases, <italic>n</italic> (%)</td><td align="left">54</td><td align="left">0</td><td align="left">3 (8.8)</td><td align="left">51 (14.0)</td><td align="left">0.600***</td></tr><tr><td align="left">Other chronic diseases <sup>a</sup>, <italic>n</italic> (%)</td><td align="left">179</td><td align="left">0</td><td align="left">18 (52.9)</td><td align="left">161 (44.4)</td><td align="left">0.336**</td></tr></tbody></table><table-wrap-foot><p><italic>CIC</italic> clean intermittent catheterization, <italic>BMI</italic> body mass index, <italic>CNS</italic> central nervous system</p><p>*Wilcoxon rank sum test</p><p>**Pearson&#x02019;s Chi-squared test</p><p>***Fisher&#x02019;s exact test</p><p><sup>a</sup>Hematological diseases, other endocrine disorders, metal disorders, lung diseases, cancer, autoimmune diseases, gastrointestinal diseases, kidney diseases, rheumatic disorders</p></table-wrap-foot></table-wrap></p><sec id="Sec9"><title>Clean Intermittent Catheterization Rate</title><p id="Par23">Out of 397, a total of 34 (8.6%) underwent CIC treatment. Median time interval between the first BTX-A treatment and PVR diagnosis was 13.5 (Q1&#x02013;Q3: 6.8&#x02013;21.3) days. Two women were diagnosed with PVR when they returned for their second BTX-A treatment, 3 months and 2 years after their initial BTX-A treatment. In the CIC group, 16 (47.1%) had a PVR volume exceeding 300&#x000a0;ml, 10 (29.4%) had a PVR between 200 and 299&#x000a0;ml, and 7 (20.6%) had a PVR lower than 200&#x000a0;ml at diagnosis. One woman in the CIC group had no PVR volume documented in the medical record. During the intervention period, one woman required a temporary indwelling catheter. In the CIC group, another woman was hospitalized with pyelonephritis 1 month after treatment. CIC duration was 8 weeks or more for 16 women (47.1%), 5 (14.7%) performed CIC for 4&#x02013;8 weeks, and 7 (20.6%) for less than 4 weeks. CIC duration was not documented in the medical records for 6 women (17.6%). Of the women who underwent CIC, 15 (44%) had more than one BTX-A treatment, whereas 19 (55.9%) did not continue BTX-A treatment.</p></sec><sec id="Sec10"><title>Gynecological History and Pretreatment Bladder Diary</title><p id="Par24">Women with a history of UUI had a 70% reduced risk of undergoing CIC (OR 0.30, 95% CI 0.09&#x02013;0.97). In the CIC group, 9 (26.5%) had a history of anterior colporrhaphy, which was associated with an increased likelihood of CIC (OR 3.86, 95% CI 1.65&#x02013;8.99). Similarly, 9 (26.5%) women had previously undergone a midurethral sling (MUS) procedure, which was predictive of CIC in the univariate analysis (OR 2.75, 95% CI 1.20&#x02013;6.29). A history of a hysterectomy procedure was associated with CIC (OR 2.13, 95% CI 1.01&#x02013;4.50; Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Risk of clean intermittent catheterization (CIC) medical history</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="5"/><th align="left" colspan="2">Univariate analysis*</th></tr><tr><th align="left">Variable</th><th align="left"><italic>N</italic></th><th align="left">Missing (<italic>n</italic>)</th><th align="left">CIC group</th><th align="left">Non-CIC group</th><th align="left">OR 95% CI</th><th align="left"><italic>p</italic> value</th></tr></thead><tbody><tr><td align="left">Age/10-year change</td><td align="left">397</td><td align="left">0</td><td align="left"/><td align="left"/><td align="left">0.88 (0.97&#x02013;1.01)</td><td align="left">0.264</td></tr><tr><td align="left">Hysterectomy, <italic>n</italic> (%)</td><td align="left">86</td><td align="left">0</td><td align="left">12 (35.3)</td><td align="left">74 (20.4)</td><td align="left">2.13 (1.01&#x02013;4.50)</td><td align="left">0.048</td></tr><tr><td align="left">Partus, <italic>n</italic> (%)</td><td align="left">392</td><td align="left">5</td><td align="left">31 (91.2)</td><td align="left">318 (87.6)</td><td align="left">1.30 (0.38&#x02013;4.45)</td><td align="left">0.676</td></tr><tr><td align="left">&#x000a0;&#x000a0;0</td><td align="left">43</td><td align="left"/><td align="left">3 (8.8)</td><td align="left">40 (11.0)</td><td align="left">1.00 (ref.)</td><td align="left"/></tr><tr><td align="left">&#x000a0;&#x000a0;1</td><td align="left">47</td><td align="left"/><td align="left">5 (14.7)</td><td align="left">42 (11.8)</td><td align="left">1.59 (0.36&#x02013;7.08)</td><td align="left">0.545</td></tr><tr><td align="left">&#x000a0; &#x02265; 2</td><td align="left">286</td><td align="left"/><td align="left">24 (70.6)</td><td align="left">262 (72.2)</td><td align="left">1.22 (0.35&#x02013;4.24)</td><td align="left">0.753</td></tr><tr><td align="left">Cesarean section, <italic>n</italic> (%)</td><td align="left">27</td><td align="left">10</td><td align="left">4 (11.8)</td><td align="left">23 (6.3)</td><td align="left">1.91 (0.62&#x02013;5.90)</td><td align="left">0.259</td></tr><tr><td align="left">Spasmolytics, <italic>n</italic> (%)</td><td align="left">371</td><td align="left">0</td><td align="left">33 (97.1)</td><td align="left">338 (93.1)</td><td align="left">2.34 (0.31&#x02013;17.87)</td><td align="left">0.411</td></tr><tr><td align="left">UUI, <italic>n</italic> (%)</td><td align="left">379</td><td align="left">0</td><td align="left">30 (88.2)</td><td align="left">349 (96.1)</td><td align="left">0.30 (0.09&#x02013;0.97)</td><td align="left">0.045</td></tr><tr><td align="left">SUI, <italic>n</italic> (%)</td><td align="left">208</td><td align="left">14</td><td align="left">14 (41.2)</td><td align="left">194 (53.4)</td><td align="left">0.59 (0.29&#x02013;1.22)</td><td align="left">0.155</td></tr><tr><td align="left">MUI, <italic>n</italic> (%)</td><td align="left">198</td><td align="left">14</td><td align="left">12 (35.3)</td><td align="left">186 (51.2)</td><td align="left">0.52 (0.25&#x02013;1.08)</td><td align="left">0.080</td></tr><tr><td align="left">Cystocele, <italic>n</italic> (%)</td><td align="left">348</td><td align="left">49</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="7">&#x000a0;&#x000a0;POP-Q stage</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;&#x000a0;0&#x02013;1</td><td align="left">296</td><td align="left"/><td align="left">24 (70.6)</td><td align="left">272 (74.9)</td><td align="left">1.00 (ref.)</td><td align="left"/></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02265; 2</td><td align="left">52</td><td align="left"/><td align="left">5 (14.7)</td><td align="left">47 (13.1)</td><td align="left">1.21 (0.44&#x02013;3.32)</td><td align="left">0.717</td></tr><tr><td align="left">Uterine prolapse, <italic>n</italic> (%)</td><td align="left">324</td><td align="left">73</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="7">&#x000a0;&#x000a0;POP-Q stage</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;&#x000a0;0&#x02013;1</td><td align="left">316</td><td align="left"/><td align="left">27 (79.4)</td><td align="left">289 (79.6)</td><td align="left">1.00 (ref.)</td><td align="left"/></tr><tr><td align="left">&#x000a0; &#x000a0; &#x02265; 2</td><td align="left">8</td><td align="left"/><td align="left">1 (2.9)</td><td align="left">7 (1.9)</td><td align="left">1.53 (0.18&#x02013;12.89)</td><td align="left">0.696</td></tr><tr><td align="left">Rectocele,<italic> n</italic> (%)</td><td align="left">339</td><td align="left">58</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="7">&#x000a0;&#x000a0;POP&#x02013;Q stage</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;&#x000a0;0&#x02013;1</td><td align="left">300</td><td align="left"/><td align="left">26 (76.5)</td><td align="left">274 (75.5)</td><td align="left">1.00 (ref.)</td><td align="left"/></tr><tr><td align="left">&#x000a0; &#x000a0; &#x02265; 2</td><td align="left">39</td><td align="left"/><td align="left">3 (8.8)</td><td align="left">36 (9.9)</td><td align="left">0.88 (0.25&#x02013;3.05)</td><td align="left">0.838</td></tr><tr><td align="left" colspan="7">Previous urogynecological surgery (<italic>N</italic>&#x02009;=&#x02009;108, missing&#x02009;=&#x02009;6)</td></tr><tr><td align="left">&#x000a0;&#x000a0;MUS, <italic>n</italic> (%)</td><td align="left">51</td><td align="left"/><td align="left">9 (26.5)</td><td align="left">42 (11.6)</td><td align="left">2.75 (1.20&#x02013;6.29)</td><td align="left">0.016</td></tr><tr><td align="left">&#x000a0;&#x000a0;Bulking, <italic>n</italic> (%)</td><td align="left">21</td><td align="left"/><td align="left">1 (2.9)</td><td align="left">20 (5.5)</td><td align="left">0.52 (0.07&#x02013;4.00)</td><td align="left">0.529</td></tr><tr><td align="left">&#x000a0;&#x000a0;Anterior colporrhaphy, <italic>n</italic> (%)</td><td align="left">40</td><td align="left"/><td align="left">9 (26.5)</td><td align="left">31 (8.5)</td><td align="left">3.86 (1.65&#x02013;8.99)</td><td align="left">0.002</td></tr><tr><td align="left">&#x000a0;&#x000a0;Posterior colporrhaphy, <italic>n</italic> (%)</td><td align="left">5</td><td align="left"/><td align="left">0</td><td align="left">5 (1.4)</td><td align="left">0 (0.00&#x02013;Inf)</td><td align="left">0.989</td></tr></tbody></table><table-wrap-foot><p><italic>CIC</italic> clean intermittent catheterization, <italic>UUI</italic> urgency urinary incontinence, <italic>SUI</italic> stress urinary incontinence, <italic>MUI</italic> mixed urinary incontinence, <italic>MUS</italic> midurethral sling, <italic>POP-Q</italic> Pelvic Organ Prolapse Quantification, <italic>OR</italic> odds ratio, <italic>CI</italic> confidence interval</p><p>*Logistic regression analysis</p></table-wrap-foot></table-wrap></p><p id="Par25">Pretreatment bladder diaries were available for 367 women. A bladder capacity of 500&#x000a0;ml or greater increased the risk of CIC more than two times (OR 2.46, 95% CI 1.06&#x02013;5.70). Reported leakages in the bladder diary were associated with a 76% lower risk of CIC (OR 0.24, 95% CI 0.10&#x02013;0.57; Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).
<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Free post-void volume and bladder diary characteristics in the clean intermittent catheterization (CIC) and non-CIC groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left"/><th align="left"/><th align="left"/><th align="left"/><th align="left" colspan="2">Univariate analysis*</th></tr><tr><th align="left">Variable</th><th align="left"><italic>N</italic></th><th align="left">Missing (<italic>n</italic>)</th><th align="left">CIC group</th><th align="left">Non-CIC group</th><th align="left">OR (95% CI)</th><th align="left"><italic>p</italic> value</th></tr></thead><tbody><tr><td align="left">Free PVR/10-ml increments, median (Q1&#x02013;Q3)</td><td align="left">397</td><td align="left">0</td><td align="left">28.5 (10&#x02013;55.3)</td><td align="left">30 (10&#x02013;50)</td><td align="left">1.02 (0.9&#x02013;1.13)</td><td align="left">0.766</td></tr><tr><td align="left" colspan="7">Bladder diary</td></tr><tr><td align="left">&#x000a0;&#x000a0;Bladder capacity/10-ml increments, median (Q1&#x02013;Q3)</td><td align="left">367</td><td align="left">30</td><td align="left">305 (250&#x02013;500)</td><td align="left">300 (220&#x02013;400)</td><td align="left">1.01 (0.98&#x02013;1.03)</td><td align="left">0.562</td></tr><tr><td align="left" colspan="7">Bladder capacity categorized/ml, <italic>n</italic> (%)</td></tr><tr><td align="left">&#x000a0; 0&#x02013;499</td><td align="left"/><td align="left"/><td align="left">20 (58.8)</td><td align="left">286 (78.8)</td><td align="left">1.00 (ref.)</td><td align="left"/></tr><tr><td align="left">&#x000a0;&#x000a0;500&#x02013;1,030</td><td align="left"/><td align="left"/><td align="left">9 (26.5)</td><td align="left">52 (14.3)</td><td align="left">2.46 (1.06&#x02013;5.70)</td><td align="left">0.035</td></tr><tr><td align="left">Micturition, median (Q1&#x02013;Q3)</td><td align="left">367</td><td align="left">30</td><td align="left">8.5 (7&#x02013;11)</td><td align="left">10 (8&#x02013;12)</td><td align="left">1.02 (0.94&#x02013;1.11)</td><td align="left">0.674</td></tr><tr><td align="left">Fluid intake/ml, median (Q1&#x02013;Q3)</td><td align="left">367</td><td align="left">30</td><td align="left">1,300.0 (1,050.0&#x02013;1,697.3)</td><td align="left">1,500 (1,175&#x02013;1,825)</td><td align="left">1.00 (1.00&#x02013;1.00)</td><td align="left">0.138</td></tr><tr><td align="left" colspan="7">Fluid intake categorized/ml, <italic>n</italic> (%)</td></tr><tr><td align="left">&#x000a0;&#x000a0;0&#x02013;1,499&#x000a0;ml</td><td align="left"/><td align="left"/><td align="left">21 (61.8)</td><td align="left">171 (47.1)</td><td align="left">1.00 (ref.)</td><td align="left"/></tr><tr><td align="left">&#x000a0;&#x000a0;&#x02265; 1,500&#x000a0;ml</td><td align="left"/><td align="left"/><td align="left">9 (26.5)</td><td align="left">166 (45.7)</td><td align="left">0.44 (0.20&#x02013;0.99)</td><td align="left">0.048</td></tr><tr><td align="left">Total voided volume/ml, median (Q1&#x02013;Q3)</td><td align="left">367</td><td align="left">30</td><td align="left">1,451.5 (1,103.8&#x02013;1,653.8)</td><td align="left">1,488.0 (1,130.0&#x02013;1,876.5)</td><td align="left">1.00 (1.00&#x02013;1.00)</td><td align="left">0.348</td></tr><tr><td align="left">Micturition volume/ml, median (Q1&#x02013;Q3)</td><td align="left">367</td><td align="left">30</td><td align="left">148 (119.5&#x02013;218.8)</td><td align="left">150 (113.8&#x02013;192.3)</td><td align="left">1.00 (1.00&#x02013;1.00)</td><td align="left">0.437</td></tr><tr><td align="left">Incontinence episodes, <italic>n</italic> (%)</td><td align="left">325</td><td align="left">33</td><td align="left">22 (64.7%)</td><td align="left">303 (83.5%)</td><td align="left">0.24 (0.10&#x02013;0.57)</td><td align="left">0.001</td></tr><tr><td align="left">Incontinence episodes, median (Q1&#x02013;Q3)</td><td align="left">324</td><td align="left">34</td><td align="left">3.5 (2&#x02013;4)</td><td align="left">5.0 (3&#x02013;8)</td><td align="left">0.82 (0.70&#x02013;0.97)</td><td align="left">0.020</td></tr></tbody></table><table-wrap-foot><p><italic>CIC</italic> clean intermittent catheterization, <italic>OR</italic> odds ratio, <italic>CI</italic> confidence interval, <italic>PVR</italic> post-void residual</p><p>*Logistic regression analysis</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec11"><title>Urodynamic Studies</title><p id="Par26">In our cohort, 318 women (80.1%) had urodynamic detrusor overactivity, which showed no difference between the CIC group and the non-CIC group (<italic>p</italic>&#x02009;=&#x02009;0.579). The CIC group had significantly greater MCC (350.0&#x000a0;ml [Q1&#x02013;Q3: 253.0&#x02013;441.5], compared with the non-CIC group (290&#x000a0;ml (Q1&#x02013;Q3: 174.0&#x02013;400.0), <italic>p</italic>&#x02009;=&#x02009;0.017). An MCC greater than 350&#x000a0;ml significantly increased the risk of CIC compared with an MCC lower than 200&#x000a0;ml (OR 3.65, 95% CI 1.20&#x02013;11.12). Cystometric incontinence (comprising both detrusor overactivity incontinence and urodynamic stress incontinence) showed an insignificant trend toward reducing the CIC risk by 50% (OR 0.50, 95% CI 0.25&#x02013;1.03, <italic>p</italic>&#x02009;=&#x02009;0.059; Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>).
<table-wrap id="Tab4"><label>Table&#x000a0;4</label><caption><p>Urodynamic parameters in the clean intermittent catheterization (CIC) and non-CIC groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="5"/><th align="left" colspan="2">Univariate analysis*</th></tr><tr><th align="left">Urodynamic parameter</th><th align="left"><italic>N</italic></th><th align="left">Missing</th><th align="left">CIC group</th><th align="left">Non-CIC group</th><th align="left">OR (95% CI)</th><th align="left"><italic>p</italic> value</th></tr></thead><tbody><tr><td align="left">First desire/ml, median (Q1&#x02013;Q3)</td><td align="left"/><td align="left"/><td align="left">147 (111&#x02013;237)</td><td align="left">138 (94&#x02013;212)</td><td align="left">1.00 (1.00&#x02013;1.01)</td><td align="left">0.453</td></tr><tr><td align="left">MCC/10-ml increments, median (Q1&#x02013;Q3)</td><td align="left">397</td><td align="left">0</td><td align="left">350.0 (253.0&#x02013;441.5)</td><td align="left">290 (174&#x02013;400)</td><td align="left">1.03 (1.00&#x02013;1.06)</td><td align="left">0.016</td></tr><tr><td align="left">MCC categorized/ml, <italic>n</italic> (%)</td><td align="left">397</td><td align="left">0</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0; &#x000a0;200 </td><td align="left"/><td align="left"/><td align="left">4 (11.8)</td><td align="left">103 (28.4)</td><td align="left">1.00 (ref.)</td><td align="left"/></tr><tr><td align="left">&#x000a0;&#x000a0;200&#x02013;349</td><td align="left"/><td align="left"/><td align="left">12 (35.3)</td><td align="left">133 (36.6)</td><td align="left">2.32 (0.73&#x02013;7.41)</td><td align="left">0.154</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x02265; 350 </td><td align="left"/><td align="left"/><td align="left">18 (52.9)</td><td align="left">127 (35.0)</td><td align="left">3.65 (1.20&#x02013;11.12)</td><td align="left">0.023</td></tr><tr><td align="left">Cystometric DO, <italic>n</italic> (%)</td><td align="left">318</td><td align="left">0</td><td align="left">26 (76.5)</td><td align="left">292 (80.4)</td><td align="left">0.79 (0.34&#x02013;1.82)</td><td align="left">0.579</td></tr><tr><td align="left">Vol. first detrusor contraction/ml, median (Q1&#x02013;Q3)</td><td align="left">318</td><td align="left">0</td><td align="left">225.0 (91.3&#x02013;335)</td><td align="left">160 (100&#x02013;280)</td><td align="left">1.00 (1.00&#x02013;1.01)</td><td align="left">0.158</td></tr><tr><td align="left">Cystometric incontinence, <italic>n</italic> (%)</td><td align="left">279</td><td align="left">0</td><td align="left">19 (55.9)</td><td align="left">260 (71.6)</td><td align="left">0.50 (0.25&#x02013;1.03)</td><td align="left">0.059</td></tr><tr><td align="left">Mixed cystometric incontinence, <italic>n</italic> (%)</td><td align="left">63</td><td align="left">0</td><td align="left">5 (14.7)</td><td align="left">58 (16.0)</td><td align="left">0.91 (0.34&#x02013;2.44)</td><td align="left">0.846</td></tr><tr><td align="left">Cystometric detrusor incontinence, <italic>n</italic> (%)</td><td align="left">242</td><td align="left">0</td><td align="left">18 (52.9)</td><td align="left">224 (61.7)</td><td align="left">0.70 (0.34&#x02013;1.41)</td><td align="left">0.318</td></tr><tr><td align="left">Cystometric stress incontinence, <italic>n</italic> (%)</td><td align="left">99</td><td align="left">0</td><td align="left">6 (17.6)</td><td align="left">93 (25.6)</td><td align="left">0.62 (0.25&#x02013;1.55)</td><td align="left">0.308</td></tr><tr><td align="left">Cystometric PVR/10-ml increments, median (Q1&#x02013;Q3)</td><td align="left">397</td><td align="left">0</td><td align="left">65.0 (0&#x02013;170.0)</td><td align="left">33.0 (0&#x02013;134.5)</td><td align="left">1.00 (1.00&#x02013;1.00)</td><td align="left">0.531</td></tr><tr><td align="left">Cystometric PVR categorized/ml, <italic>n</italic> (%)</td><td align="left">397</td><td align="left">0</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;&#x000a0;0&#x02013;49</td><td align="left"/><td align="left"/><td align="left">15 (44.1)</td><td align="left">201 (55.4)</td><td align="left">1.00 (ref.)</td><td align="left"/></tr><tr><td align="left">&#x000a0;&#x000a0;&#x02265; 50</td><td align="left"/><td align="left"/><td align="left">19 (52.9)</td><td align="left">162 (44.6)</td><td align="left">1.57 (0.77&#x02013;3.19)</td><td align="left">0.211</td></tr><tr><td align="left">Cystometric PVR categorized/ml, <italic>n</italic> (%)</td><td align="left">397</td><td align="left">0</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;&#x000a0;0&#x02013;99</td><td align="left"/><td align="left"/><td align="left">20 (58.8)</td><td align="left">249 (68.6)</td><td align="left">1.00 (ref.)</td><td align="left"/></tr><tr><td align="left">&#x000a0; &#x02265;&#x000a0;100</td><td align="left"/><td align="left"/><td align="left">14 (41.2)</td><td align="left">114 (31.4)</td><td align="left">1.53 (0.75&#x02013;3.13)</td><td align="left">0.247</td></tr></tbody></table><table-wrap-foot><p><italic>MCC</italic> maximum cystometric capacity, <italic>DO</italic> detrusor overactivity, <italic>PVR</italic> post-void residual, <italic>OR</italic> odds ratio, <italic>CI</italic> confidence interval</p><p>*Logistic regression analysis</p></table-wrap-foot></table-wrap></p><p id="Par27">In a multivariate logistic regression analysis, previous anterior colporrhaphy (OR 3.71, 95% CI 1.52&#x02013;9.06) and 10-ml increments in MCC (OR 1.03, 95% CI 1.00&#x02013;1.06) were identified as predictive factors for CIC, whereas UUI was a protective factor for CIC (OR 0.23, 95% CI 0.07&#x02013;0.79). The association between MUS and CIC lost statistical significance, although a trend indicated an increased risk of CIC in the multivariate analysis (Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>).
<table-wrap id="Tab5"><label>Table&#x000a0;5</label><caption><p>Risk indicators associated with clean intermittent catheterization (CIC) after intradetrusor onabotulinumtoxinA (BTX-A) treatment</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left" colspan="2">Univariate analysis*</th><th align="left" colspan="2">Multivariate analysis*</th></tr><tr><th align="left">Variable</th><th align="left">OR (95% CI)</th><th align="left"><italic>p</italic> value</th><th align="left">OR (95% CI)</th><th align="left"><italic>p</italic> value</th></tr></thead><tbody><tr><td align="left">UUI</td><td align="left">0.30 (0.09&#x02013;0.97)</td><td align="left">0.045</td><td char="." align="left">0.23 (0.07&#x02013;0.79)</td><td char="." align="left">0.019</td></tr><tr><td align="left">MUS</td><td char="." align="left">2.75 (1.20&#x02013;6.29)</td><td align="left">0.016</td><td char="." align="left">1.96 (0.81&#x02013;4.71)</td><td char="." align="left">0.134</td></tr><tr><td align="left">Anterior colporrhaphy</td><td char="." align="left">3.86 (1.65&#x02013;8.99)</td><td char="." align="left">0.002</td><td char="." align="left">3.71 (1.52&#x02013;9.06)</td><td char="." align="left">0.004</td></tr><tr><td align="left">MCC/10-ml increments</td><td char="." align="left">1.03 (1.00&#x02013;1.01)</td><td char="." align="left">0.016</td><td char="." align="left">1.03 (1.00&#x02013;1.06)</td><td char="." align="left">0.038</td></tr></tbody></table><table-wrap-foot><p><italic>UUI</italic> urgency urinary incontinence, <italic>MUS</italic> midurethral sling, <italic>MCC</italic> maximum cystometric capacity, <italic>OR</italic> odds ratio, <italic>CI</italic> confidence interval</p><p>*Logistic regression analysis</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec12"><title>Discussion</title><sec id="Sec13"><title>Clean Intermittent Catheterization Rate</title><p id="Par28">In our retrospective cohort of 397 women, we report a CIC rate of 8.6% following the first BTX-A treatment. CIC rates following the first BTX-A treatment have been reported to be as high as 48.9% [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR11">11</xref>]. A recent meta-analysis comprising 10 RCTs evaluating BTX-A compared with placebo reported an RR of 8.89 (95% CI 4.39&#x02013;17.6) for developing urinary retention or CIC [<xref ref-type="bibr" rid="CR1">1</xref>]. Another meta-analysis reported an RR of 13.99 (95% CI 5.71&#x02013;34.30) for urinary retention in patients receiving BTX-A treatment with 100 Units [<xref ref-type="bibr" rid="CR12">12</xref>]. RCTs have reported lower CIC rates. Nitti et al. reported a CIC rate of 6.1% in an RCT with a PVR indication similar to that of our study [<xref ref-type="bibr" rid="CR4">4</xref>], whereas Chapple et al. reported a CIC rate of 6.9% [<xref ref-type="bibr" rid="CR2">2</xref>]. Conversely, cohort studies have reported higher CIC numbers. Squires et al. found a 10% CIC rate among 187 women receiving their first BTX-A treatment for idiopathic UUI in a retrospective cohort. Authors defined urinary retention as incomplete bladder emptying, worsened urgency or frequency, difficulty voiding, suprapubic pain, with PVR greater than 150&#x000a0;ml, or PVR greater than 300&#x000a0;ml without bladder symptoms [<xref ref-type="bibr" rid="CR13">13</xref>]. Osborn et al. reported a CIC rate of 21% in 101 patients (76% women) with idiopathic OAB who had their first BTX-A treatment. CIC indication was based on the patients&#x02019; symptoms, with only 24% of those undergoing CIC having a post-treatment PVR [<xref ref-type="bibr" rid="CR14">14</xref>].</p><p id="Par29">Variability in reported CIC rates in the literature may be due to different definitions of PVR, as concluded in a recent review by Abrar et al. [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par30">Among women who initiated CIC in our study, 47.1% presented with a PVR exceeding 300&#x000a0;ml at the time of diagnosis, which is higher than reported in the literature. The RCT by Chapple et al. found that 10.2% of patients requiring CIC had a postoperative PVR volume of 200&#x000a0;ml or greater [<xref ref-type="bibr" rid="CR2">2</xref>]. Our clinic does not routinely schedule postoperative follow-ups for all women unless the health care provider assesses a potential risk. Furthermore, our criteria for initiating CIC were based on larger post-treatment PVRs, as our clinical guideline defines PVR requiring CIC as PVR greater than 200&#x000a0;ml with clinical symptoms or PVR greater than 350&#x000a0;ml without symptoms. Our criteria for initiating CIC are more conservative than those of many previous studies, which could explain a lower CIC rate in our cohort. Redundant controls could result in unnecessary CIC prescriptions, potentially causing adverse effects that outweigh the risk of missing an elevated PVR. One woman who required CIC in our cohort was admitted with pyelonephritis.</p><p id="Par31">American Urological Association defines non-neurogenic chronic urinary retention as an elevated PVR exceeding 300&#x000a0;ml persisting for at least 6 months and documented on two or more separate occasions [<xref ref-type="bibr" rid="CR15">15</xref>]. International Urogynecological Association/ICS Joint Report defines chronic urinary retention as a nonpainful bladder with a chronically high PVR greater than 200&#x000a0;ml [<xref ref-type="bibr" rid="CR16">16</xref>]. The lack of a standardized definition for urinary retention contributes to the lack of consensus on when to initiate CIC.</p><p id="Par32">Women who received perioperative antibiotics, including both intravenous and peroral administration, had a threefold increased risk of undergoing CIC. UTI could potentially confound this association. Abrar et al. reported that patients requiring CIC (43.8%, <italic>n</italic>&#x02009;=&#x02009;32) had 5.3 times higher odds of developing UTI than those who did not require CIC [<xref ref-type="bibr" rid="CR6">6</xref>], suggesting that CIC might be associated with UTI due to instrumentation.</p><p id="Par33">Urinary retention could also be a confounding factor for both UTIs and CIC. Perioperative antibiotics administration may be influenced by the health care provider assessing an increased UTI risk, potentially biasing our results through indication bias.</p><p id="Par34">Clean intermittent catheterization was initiated at a median of 13.50 (Q1&#x02013;Q3 6.8&#x02013;21.3) days. However, two women were diagnosed with asymptomatic PVR requiring initiation of CIC when they returned for their second BTX-A treatment, 3 months and 2 years after their first treatment respectively. Liberman et al. found that 80% of their patients initiated CIC within 4 weeks [<xref ref-type="bibr" rid="CR17">17</xref>]. A previous RCT observed a peak in mean PVR around week 2 following BTX-A treatment, followed by a gradual decrease between weeks 4 and 12 [<xref ref-type="bibr" rid="CR8">8</xref>], whereas CIC was initiated in almost all within 12&#x000a0;weeks in the RCT by Chapple et al. [<xref ref-type="bibr" rid="CR2">2</xref>].</p><p id="Par35">In our cohort, nearly half of women in the CIC group (47.1%) performed CIC for over 8 weeks, whereas 7 (20.6%) performed CIC in 4 weeks or less. Osborn et al. reported a mean length of urinary retention for 16&#x000a0;weeks in their cohort [<xref ref-type="bibr" rid="CR14">14</xref>], whereas mean duration of urinary retention has been reported ranging from 9 weeks [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR15">15</xref>] to 9 months [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR18">18</xref>&#x02013;<xref ref-type="bibr" rid="CR20">20</xref>]. The exact duration of CIC for each woman in our cohort was not determined owing to the retrospective nature of the study and incomplete information in the medical records.</p></sec><sec id="Sec14"><title>Gynecological History</title><p id="Par36">Age was not a predictive factor for CIC in our cohort. This contrasts with previous studies that did identify higher age as a predictor of CIC [<xref ref-type="bibr" rid="CR21">21</xref>]. A high median age in our cohort could explain the lack of association.</p><p id="Par37">We found a significant association between a previous anterior colporrhaphy and an increased likelihood of CIC, which was confirmed in the multivariate analysis. Urinary retention is a well-known and early postoperative adverse effect following anterior colporrhaphy [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. However, to our knowledge, urinary retention has not been identified in the literature as a long-term adverse effect or as a risk factor for CIC after BTX-A treatment. Our results contradict those of previous studies on adverse events following prolapse surgery, which showed improvements in bladder emptying and reduced PVR volumes [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Confounding factors could influence this novel observed association.</p><p id="Par38">Moreover, we found an association between previous MUS and the risk of CIC in the univariate analysis. This association lost statistical significance in the multivariate analysis, although a trend suggesting an increased risk of CIC persisted. No significant association between CIC and a history of urethral bulking procedure was found. Squires et al. reported that women with a history of anti-incontinence procedures for stress urinary incontinence were more likely to experience urinary retention (53% vs 18%, <italic>p</italic>&#x02009;=&#x02009;0.002), although they did not have higher baseline PVR (32&#x000a0;ml vs 26&#x000a0;ml, <italic>p</italic>&#x02009;=&#x02009;0.3) in a cohort of 187 women undergoing BTX-A treatment [<xref ref-type="bibr" rid="CR13">13</xref>]. However, the anti-incontinence procedure types were not specified in the study. Voiding dysfunction is common following MUS but is often transient and self-limiting [<xref ref-type="bibr" rid="CR26">26</xref>]. Prolonged catheterization for more than 2&#x02013;4 days postoperatively owing to urinary retention after MUS has been reported to be 5.6% in a retrospective cohort of 17,030 patients [<xref ref-type="bibr" rid="CR27">27</xref>]. In our cohort, 10.1% of women had previously undergone an anterior colporrhaphy, and 26.5% of the CIC group had undergone this procedure. Similarly, 12.8% underwent MUS, and 26.5% of the CIC group had undergone this procedure. These findings provide novel and valuable results and should be considered when advising women with a history of previous urogynecological surgery.</p><p id="Par39">Women who had undergone hysterectomy before their first BTX-A treatment had an increased risk of CIC. This association was also reported by Abrar et al. (OR 4.55, 95% CI 1.09&#x02013;18.87) in their cohort of 74 women with a CIC rate of 43.8% [<xref ref-type="bibr" rid="CR6">6</xref>].</p></sec><sec id="Sec15"><title>Pretreatment Post-Void Residual</title><p id="Par40">Post-void residual was not a significant predictor for CIC, whether adjusted for MCC or analyzed as a continuous or categorized variable. An increased pretreatment PVR is a well-known risk factor for post-treatment PVR requiring CIC [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. Kuo et al. found a baseline PVR of 100&#x000a0;ml or greater to predict CIC (OR 9.9, 95% CI 7.2&#x02013;44.7) [<xref ref-type="bibr" rid="CR28">28</xref>]. Our results contrast with those of previous studies that identified pretreatment PVR as a predictor of CIC. The absence of a significant association between pretreatment PVR and post-treatment CIC in our study could be explained by low pretreatment PVR measurements. All of the women included had a pretreatment PVR lower than 100&#x000a0;ml in the UDS, emphasizing that we carry out a careful assessment before referring our patients for BTX-A treatment. Squires et al. reported similar results to those of our study, with no association between pretreatment PVR and post-treatment urinary retention (25&#x02009;&#x000b1;&#x02009;27&#x000a0;ml vs 46&#x02009;&#x000b1;&#x02009;52&#x000a0;ml, <italic>p</italic>&#x02009;=&#x02009;0.12) [<xref ref-type="bibr" rid="CR13">13</xref>].</p></sec><sec id="Sec16"><title>Urodynamic Studies</title><p id="Par41">Urodynamic studies are considered the gold standard for investigating lower urinary tract dysfunction [<xref ref-type="bibr" rid="CR29">29</xref>].</p><p id="Par42">In our study, the CIC group had a significantly greater MCC than the non-CIC group (350.0&#x000a0;ml [Q1&#x02013;Q3 253.0&#x02013;441.5] vs 290.0&#x000a0;ml [Q1&#x02013;Q3 174.0&#x02013;400.0], <italic>p</italic>&#x02009;=&#x02009;0.017). A 10-ml increment in MCC increased the risk of CIC by 3% (OR 1.03, 95% CI 1.00&#x02013;1.06), and MCC of 350&#x000a0;ml or greater increased the risk of CIC by more than threefold (OR 3.65, 95% CI 1.20&#x02013;11.12, <italic>p</italic>&#x02009;=&#x02009;0.023). Our results are supported by a previous study that reported similar associations [<xref ref-type="bibr" rid="CR14">14</xref>]. However, Squires et al. found no differences in MCC between the groups (359&#x02009;&#x000b1;&#x02009;150 vs 321&#x02009;&#x000b1;&#x02009;105, <italic>p</italic>&#x02009;=&#x02009;0.64) [<xref ref-type="bibr" rid="CR13">13</xref>].</p></sec><sec id="Sec17"><title>Bladder Diary</title><p id="Par43">Elevated bladder capacity and reported leakages in pretreatment bladder diaries were predictive of CIC, aligning with the risk factors identified through UDS. Based on these findings, the results of pretreatment UDS provided limited additional information on the risk of CIC compared with the bladder diary. Our findings suggest that bladder diaries could serve as valuable assessment tools when counseling women undergoing BTX-A treatments.</p></sec><sec id="Sec18"><title>Strengths and Limitations</title><p id="Par44">The strengths of our study lie in the assessment of a consecutive single-center cohort of women who had BTX-A treatment at our department. We evaluated an unselected cohort with baseline UDS as the most important inclusion criterion, thereby presenting clinically relevant results. Existing studies have reviewed cohorts with UDS as a subgroup. Our cohort only comprised women, whereas numerous other studies included a mixed population of women and men, possibly contributing to higher CIC rates. Men undergoing BTX-A treatment are at a higher risk of post-treatment CIC [<xref ref-type="bibr" rid="CR10">10</xref>]. In addition, this study is to our knowledge the first to identify an association between CIC and previous anterior colporrhaphy, likely because it is the first to be conducted on a large female population.</p><p id="Par45">Limitations include the retrospective nature of the study. CIC reporting was based on journal notes from the medical records, with missing documentation and information. Also, we may have underestimated the CIC rate because we do not systematically assess for PVR, potentially missing patients with asymptomatic PVR greater than 350&#x000a0;ml.</p></sec></sec><sec id="Sec19" sec-type="conclusion"><title>Conclusion</title><p id="Par46">In this retrospective cohort comprising 397 women undergoing their first BTX-A treatment, we report a CIC rate of 8.6%. Women with a history of anterior colporrhaphy were at a risk of CIC nearly four times higher. We confirm an association between increased MCC and the risk of CIC. Women with UUI were at a lower risk of initiating CIC. Elevated bladder capacity and a lack of reported leakages in pretreatment bladder diaries predicted CIC, aligning with the risk factors identified through UDS.</p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Authors&#x02019; Contributions</title><p>M. El Issaoui: project development, data collection, manuscript writing; S. Elissaoui: data collection, manuscript writing; M. Elmelund: project development, manuscript writing; N. Klarskov: project development, data collection, manuscript writing.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open access funding provided by Copenhagen University</p></notes><notes notes-type="data-availability"><title>Data Availability</title><p>Data is unfortunately not available due to the Danish Data Protection Agency&#x02019;s rules because the data contains&#x000a0;sensitive information.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics Approval</title><p id="Par47">None. The study was approved by the Capital Region&#x02019;s Knowledge Center for Data Reviews (ID: R-21013125).</p></notes><notes id="FPar2" notes-type="COI-statement"><title>Conflicts of Interest</title><p id="Par48">None.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Farag</surname><given-names>F</given-names></name><name><surname>Sakalis</surname><given-names>VI</given-names></name><name><surname>Arteaga</surname><given-names>SM</given-names></name><name><surname>Sihra</surname><given-names>N</given-names></name><name><surname>Karavitakis</surname><given-names>M</given-names></name><name><surname>Arlandis</surname><given-names>S</given-names></name><etal/></person-group><article-title>What are the short-term benefits and potential harms of therapeutic modalities for the management of overactive bladder syndrome in women? A review of evidence under the auspices of the European Association of Urology, female non-neurogenic lower urinary tract symptoms guidelines panel</article-title><source>Eur Urol</source><year>2023</year><volume>84</volume><fpage>302</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1016/J.EURURO.2023.05.014</pub-id><pub-id pub-id-type="pmid">37331921</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Farag F, Sakalis VI, Arteaga SM, Sihra N, Karavitakis M, Arlandis S, et al. What are the short-term benefits and potential harms of therapeutic modalities for the management of overactive bladder syndrome in women? A review of evidence under the auspices of the European Association of Urology, female non-neurogenic lower urinary tract symptoms guidelines panel. Eur Urol. 2023;84:302&#x02013;12. 10.1016/J.EURURO.2023.05.014.<pub-id pub-id-type="pmid">37331921</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Chapple</surname><given-names>C</given-names></name><name><surname>Sievert</surname><given-names>KD</given-names></name><name><surname>Macdiarmid</surname><given-names>S</given-names></name><name><surname>Khullar</surname><given-names>V</given-names></name><name><surname>Radziszewski</surname><given-names>P</given-names></name><name><surname>Nardo</surname><given-names>C</given-names></name><etal/></person-group><article-title>OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial</article-title><source>Eur Urol</source><year>2013</year><volume>64</volume><fpage>249</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1016/J.EURURO.2013.04.001</pub-id><pub-id pub-id-type="pmid">23608668</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Chapple C, Sievert KD, Macdiarmid S, Khullar V, Radziszewski P, Nardo C, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2013;64:249&#x02013;56. 10.1016/J.EURURO.2013.04.001.<pub-id pub-id-type="pmid">23608668</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Tincello</surname><given-names>DG</given-names></name><name><surname>Kenyon</surname><given-names>S</given-names></name><name><surname>Abrams</surname><given-names>KR</given-names></name><name><surname>Mayne</surname><given-names>C</given-names></name><name><surname>Toozs-Hobson</surname><given-names>P</given-names></name><name><surname>Taylor</surname><given-names>D</given-names></name><etal/></person-group><article-title>Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study)</article-title><source>Eur Urol</source><year>2012</year><volume>62</volume><fpage>507</fpage><lpage>514</lpage><pub-id pub-id-type="doi">10.1016/J.EURURO.2011.12.056</pub-id><pub-id pub-id-type="pmid">22236796</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Tincello DG, Kenyon S, Abrams KR, Mayne C, Toozs-Hobson P, Taylor D, et al. Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study). Eur Urol. 2012;62:507&#x02013;14. 10.1016/J.EURURO.2011.12.056.<pub-id pub-id-type="pmid">22236796</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Nitti</surname><given-names>VW</given-names></name><name><surname>Dmochowski</surname><given-names>R</given-names></name><name><surname>Herschorn</surname><given-names>S</given-names></name><name><surname>Sand</surname><given-names>P</given-names></name><name><surname>Thompson</surname><given-names>C</given-names></name><name><surname>Nardo</surname><given-names>C</given-names></name><etal/></person-group><article-title>OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized placebo controlled trial</article-title><source>J Urol</source><year>2017</year><volume>197</volume><fpage>S216</fpage><lpage>S223</lpage><pub-id pub-id-type="doi">10.1016/J.JURO.2016.10.109</pub-id><pub-id pub-id-type="pmid">28012773</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized placebo controlled trial. J Urol. 2017;197:S216&#x02013;23. 10.1016/J.JURO.2016.10.109.<pub-id pub-id-type="pmid">28012773</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Abrar</surname><given-names>M</given-names></name><name><surname>Pindoria</surname><given-names>N</given-names></name><name><surname>Malde</surname><given-names>S</given-names></name><name><surname>Chancellor</surname><given-names>M</given-names></name><name><surname>DeRidder</surname><given-names>D</given-names></name><name><surname>Sahai</surname><given-names>A</given-names></name></person-group><article-title>Predictors of poor response and adverse events following botulinum toxin a for refractory idiopathic overactive bladder: a systematic review</article-title><source>Eur Urol Focus</source><year>2021</year><volume>7</volume><fpage>1448</fpage><lpage>1467</lpage><pub-id pub-id-type="doi">10.1016/J.EUF.2020.06.013</pub-id><pub-id pub-id-type="pmid">32616412</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Abrar M, Pindoria N, Malde S, Chancellor M, DeRidder D, Sahai A. Predictors of poor response and adverse events following botulinum toxin a for refractory idiopathic overactive bladder: a systematic review. Eur Urol Focus. 2021;7:1448&#x02013;67. 10.1016/J.EUF.2020.06.013.<pub-id pub-id-type="pmid">32616412</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Abrar</surname><given-names>M</given-names></name><name><surname>Stroman</surname><given-names>L</given-names></name><name><surname>Malde</surname><given-names>S</given-names></name><name><surname>Solomon</surname><given-names>E</given-names></name><name><surname>Sahai</surname><given-names>A</given-names></name></person-group><article-title>Predictors of poor response and adverse events following botulinum toxin-A for refractory idiopathic overactive bladder</article-title><source>Urology</source><year>2020</year><volume>135</volume><fpage>32</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.urology.2019.08.054</pub-id><pub-id pub-id-type="pmid">31626856</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Abrar M, Stroman L, Malde S, Solomon E, Sahai A. Predictors of poor response and adverse events following botulinum toxin-A for refractory idiopathic overactive bladder. Urology. 2020;135:32&#x02013;7. 10.1016/j.urology.2019.08.054.<pub-id pub-id-type="pmid">31626856</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Balchandra</surname><given-names>P</given-names></name><name><surname>Rogerson</surname><given-names>L</given-names></name></person-group><article-title>Women&#x02019;s perspective: intra-detrusor Botox versus sacral neuromodulation for overactive bladder symptoms after unsuccessful anticholinergic treatment</article-title><source>Int Urogynecol J</source><year>2014</year><volume>25</volume><fpage>1059</fpage><lpage>1064</lpage><pub-id pub-id-type="doi">10.1007/S00192-014-2360-7</pub-id><pub-id pub-id-type="pmid">24633067</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Balchandra P, Rogerson L. Women&#x02019;s perspective: intra-detrusor Botox versus sacral neuromodulation for overactive bladder symptoms after unsuccessful anticholinergic treatment. Int Urogynecol J. 2014;25:1059&#x02013;64. 10.1007/S00192-014-2360-7.<pub-id pub-id-type="pmid">24633067</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Dmochowski</surname><given-names>R</given-names></name><name><surname>Chapple</surname><given-names>C</given-names></name><name><surname>Nitti</surname><given-names>VW</given-names></name><name><surname>Chancellor</surname><given-names>M</given-names></name><name><surname>Everaert</surname><given-names>K</given-names></name><name><surname>Thompson</surname><given-names>C</given-names></name><etal/></person-group><article-title>Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial</article-title><source>J Urol</source><year>2010</year><volume>184</volume><fpage>2416</fpage><lpage>2422</lpage><pub-id pub-id-type="doi">10.1016/J.JURO.2010.08.021</pub-id><pub-id pub-id-type="pmid">20952013</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Dmochowski R, Chapple C, Nitti VW, Chancellor M, Everaert K, Thompson C, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol. 2010;184:2416&#x02013;22. 10.1016/J.JURO.2010.08.021.<pub-id pub-id-type="pmid">20952013</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Kessler</surname><given-names>TM</given-names></name><name><surname>Khan</surname><given-names>S</given-names></name><name><surname>Panicker</surname><given-names>J</given-names></name><name><surname>Roosen</surname><given-names>A</given-names></name><name><surname>Elneil</surname><given-names>S</given-names></name><name><surname>Fowler</surname><given-names>CJ</given-names></name></person-group><article-title>Clean intermittent self-catheterization after botulinum neurotoxin type A injections: short-term effect on quality of life</article-title><source>Obstet Gynecol</source><year>2009</year><volume>113</volume><fpage>1046</fpage><lpage>1051</lpage><pub-id pub-id-type="doi">10.1097/AOG.0B013E3181A1F5EA</pub-id><pub-id pub-id-type="pmid">19384119</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Kessler TM, Khan S, Panicker J, Roosen A, Elneil S, Fowler CJ. Clean intermittent self-catheterization after botulinum neurotoxin type A injections: short-term effect on quality of life. Obstet Gynecol. 2009;113:1046&#x02013;51. 10.1097/AOG.0B013E3181A1F5EA.<pub-id pub-id-type="pmid">19384119</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Reynolds</surname><given-names>WS</given-names></name><name><surname>Suskind</surname><given-names>AM</given-names></name><name><surname>Anger</surname><given-names>JT</given-names></name><name><surname>Brucker</surname><given-names>BM</given-names></name><name><surname>Cameron</surname><given-names>AP</given-names></name><name><surname>Chung</surname><given-names>DE</given-names></name><etal/></person-group><article-title>Incomplete bladder emptying and urinary tract infections after botulinum toxin injection for overactive bladder: multi-institutional collaboration from the SUFU research network</article-title><source>Neurourol Urodyn</source><year>2022</year><volume>41</volume><fpage>662</fpage><lpage>671</lpage><pub-id pub-id-type="doi">10.1002/nau.24871</pub-id><pub-id pub-id-type="pmid">35019167</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Reynolds WS, Suskind AM, Anger JT, Brucker BM, Cameron AP, Chung DE, et al. Incomplete bladder emptying and urinary tract infections after botulinum toxin injection for overactive bladder: multi-institutional collaboration from the SUFU research network. Neurourol Urodyn. 2022;41:662&#x02013;71. 10.1002/nau.24871.<pub-id pub-id-type="pmid">35019167</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Faure Walker</surname><given-names>NA</given-names></name><name><surname>Syed</surname><given-names>O</given-names></name><name><surname>Malde</surname><given-names>S</given-names></name><name><surname>Taylor</surname><given-names>C</given-names></name><name><surname>Sahai</surname><given-names>A</given-names></name></person-group><article-title>Onabotulinum toxin a injections in men with refractory idiopathic detrusor overactivity</article-title><source>Urology</source><year>2019</year><volume>123</volume><fpage>242</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1016/j.urology.2018.09.016</pub-id><pub-id pub-id-type="pmid">30266377</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Faure Walker NA, Syed O, Malde S, Taylor C, Sahai A. Onabotulinum toxin a injections in men with refractory idiopathic detrusor overactivity. Urology. 2019;123:242&#x02013;6. 10.1016/j.urology.2018.09.016.<pub-id pub-id-type="pmid">30266377</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>QQ</given-names></name><name><surname>Xu</surname><given-names>YQ</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Ding</surname><given-names>XY</given-names></name><name><surname>Guo</surname><given-names>C</given-names></name></person-group><article-title>Meta-analysis of randomized controlled trials using botulinum toxin A at different dosages for urinary incontinence in patients with overactive bladder</article-title><source>Front Pharmacol</source><year>2020</year><volume>10</volume><fpage>464578</fpage><pub-id pub-id-type="doi">10.3389/FPHAR.2019.01618/BIBTEX</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Gong QQ, Xu YQ, Xu J, Ding XY, Guo C. Meta-analysis of randomized controlled trials using botulinum toxin A at different dosages for urinary incontinence in patients with overactive bladder. Front Pharmacol. 2020;10:464578. 10.3389/FPHAR.2019.01618/BIBTEX.</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Squires</surname><given-names>NA</given-names></name><name><surname>Mueller</surname><given-names>MG</given-names></name><name><surname>Lewicky-Gaupp</surname><given-names>C</given-names></name><name><surname>Collins</surname><given-names>SA</given-names></name><name><surname>Kenton</surname><given-names>KS</given-names></name><name><surname>Geynisman-Tan</surname><given-names>J</given-names></name></person-group><article-title>The first injection: rates of urinary retention in women with urgency incontinence treated with intravesical onabotulinumtoxinA injection</article-title><source>Female Pelvic Med Reconstr Surg</source><year>2021</year><volume>27</volume><fpage>e118</fpage><lpage>e121</lpage><pub-id pub-id-type="doi">10.1097/SPV.0000000000000847</pub-id><pub-id pub-id-type="pmid">32487882</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Squires NA, Mueller MG, Lewicky-Gaupp C, Collins SA, Kenton KS, Geynisman-Tan J. The first injection: rates of urinary retention in women with urgency incontinence treated with intravesical onabotulinumtoxinA injection. Female Pelvic Med Reconstr Surg. 2021;27:e118&#x02013;21. 10.1097/SPV.0000000000000847.<pub-id pub-id-type="pmid">32487882</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Osborn</surname><given-names>DJ</given-names></name><name><surname>Kaufman</surname><given-names>MR</given-names></name><name><surname>Mock</surname><given-names>S</given-names></name><name><surname>Guan</surname><given-names>MJ</given-names></name><name><surname>Dmochowski</surname><given-names>RR</given-names></name><name><surname>Reynolds</surname><given-names>WS</given-names></name></person-group><article-title>Urinary retention rates after intravesical onabotulinumtoxinA injection for idiopathic overactive bladder in clinical practice and predictors of this outcome</article-title><source>Neurourol Urodyn</source><year>2015</year><volume>34</volume><fpage>675</fpage><lpage>678</lpage><pub-id pub-id-type="doi">10.1002/NAU.22642</pub-id><pub-id pub-id-type="pmid">24975819</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Osborn DJ, Kaufman MR, Mock S, Guan MJ, Dmochowski RR, Reynolds WS. Urinary retention rates after intravesical onabotulinumtoxinA injection for idiopathic overactive bladder in clinical practice and predictors of this outcome. Neurourol Urodyn. 2015;34:675&#x02013;8. 10.1002/NAU.22642.<pub-id pub-id-type="pmid">24975819</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Stoffel</surname><given-names>JT</given-names></name><name><surname>Peterson</surname><given-names>AC</given-names></name><name><surname>Sandhu</surname><given-names>JS</given-names></name><name><surname>Suskind</surname><given-names>AM</given-names></name><name><surname>Wei</surname><given-names>JT</given-names></name><name><surname>Lightner</surname><given-names>DJ</given-names></name></person-group><article-title>AUA white paper on nonneurogenic chronic urinary retention: consensus definition, treatment algorithm, and outcome end points</article-title><source>J Urol</source><year>2017</year><volume>198</volume><fpage>153</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1016/J.JURO.2017.01.075</pub-id><pub-id pub-id-type="pmid">28163030</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Stoffel JT, Peterson AC, Sandhu JS, Suskind AM, Wei JT, Lightner DJ. AUA white paper on nonneurogenic chronic urinary retention: consensus definition, treatment algorithm, and outcome end points. J Urol. 2017;198:153&#x02013;60. 10.1016/J.JURO.2017.01.075.<pub-id pub-id-type="pmid">28163030</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Haylen</surname><given-names>BT</given-names></name><name><surname>De Ridder</surname><given-names>D</given-names></name><name><surname>Freeman</surname><given-names>RM</given-names></name><name><surname>Swift</surname><given-names>SE</given-names></name><name><surname>Berghmans</surname><given-names>B</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><etal/></person-group><article-title>An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction</article-title><source>Int Urogynecol J</source><year>2010</year><volume>21</volume><fpage>5</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1007/S00192-009-0976-9</pub-id><pub-id pub-id-type="pmid">19937315</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Haylen BT, De Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 2010;21:5&#x02013;26. 10.1007/S00192-009-0976-9.<pub-id pub-id-type="pmid">19937315</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Liberman</surname><given-names>D</given-names></name><name><surname>Milhouse</surname><given-names>O</given-names></name><name><surname>Johnson-Mitchell</surname><given-names>M</given-names></name><name><surname>Siegel</surname><given-names>SW</given-names></name></person-group><article-title>Real-world retention rates after intravesical OnabotulinumtoxinA for idiopathic overactive bladder</article-title><source>Female Pelvic Med Reconstr Surg</source><year>2018</year><volume>24</volume><fpage>404</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1097/SPV.0000000000000496</pub-id><pub-id pub-id-type="pmid">28953573</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Liberman D, Milhouse O, Johnson-Mitchell M, Siegel SW. Real-world retention rates after intravesical OnabotulinumtoxinA for idiopathic overactive bladder. Female Pelvic Med Reconstr Surg. 2018;24:404&#x02013;7. 10.1097/SPV.0000000000000496.<pub-id pub-id-type="pmid">28953573</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>S</given-names></name><name><surname>Kessler</surname><given-names>TM</given-names></name><name><surname>Apostolidis</surname><given-names>A</given-names></name><name><surname>Kalsi</surname><given-names>V</given-names></name><name><surname>Panicker</surname><given-names>J</given-names></name><name><surname>Roosen</surname><given-names>A</given-names></name><etal/></person-group><article-title>What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type A injection</article-title><source>J Urol</source><year>2009</year><volume>181</volume><fpage>1773</fpage><lpage>1778</lpage><pub-id pub-id-type="doi">10.1016/J.JURO.2008.11.110</pub-id><pub-id pub-id-type="pmid">19233414</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Khan S, Kessler TM, Apostolidis A, Kalsi V, Panicker J, Roosen A, et al. What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type A injection. J Urol. 2009;181:1773&#x02013;8. 10.1016/J.JURO.2008.11.110.<pub-id pub-id-type="pmid">19233414</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Jeffery</surname><given-names>S</given-names></name><name><surname>Fynes</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Williams</surname><given-names>L</given-names></name><name><surname>Morley</surname><given-names>R</given-names></name></person-group><article-title>Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity</article-title><source>BJU Int</source><year>2007</year><volume>100</volume><fpage>1302</fpage><lpage>1306</lpage><pub-id pub-id-type="doi">10.1111/J.1464-410X.2007.07186.X</pub-id><pub-id pub-id-type="pmid">17979928</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Jeffery S, Fynes M, Lee F, Wang K, Williams L, Morley R. Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity. BJU Int. 2007;100:1302&#x02013;6. 10.1111/J.1464-410X.2007.07186.X.<pub-id pub-id-type="pmid">17979928</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Schmid</surname><given-names>DM</given-names></name><name><surname>Sauermann</surname><given-names>P</given-names></name><name><surname>Werner</surname><given-names>M</given-names></name><name><surname>Schuessler</surname><given-names>B</given-names></name><name><surname>Blick</surname><given-names>N</given-names></name><name><surname>Muentener</surname><given-names>M</given-names></name><etal/></person-group><article-title>Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics</article-title><source>J Urol</source><year>2006</year><volume>176</volume><fpage>177</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1016/S0022-5347(06)00590-8</pub-id><pub-id pub-id-type="pmid">16753396</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Schmid DM, Sauermann P, Werner M, Schuessler B, Blick N, Muentener M, et al. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol. 2006;176:177&#x02013;85. 10.1016/S0022-5347(06)00590-8.<pub-id pub-id-type="pmid">16753396</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Miotla</surname><given-names>P</given-names></name><name><surname>Cartwright</surname><given-names>R</given-names></name><name><surname>Skorupska</surname><given-names>K</given-names></name><name><surname>Bogusiewicz</surname><given-names>M</given-names></name><name><surname>Markut-Miotla</surname><given-names>E</given-names></name><name><surname>Futyma</surname><given-names>K</given-names></name><etal/></person-group><article-title>Urinary retention in female OAB after intravesical Botox injection: who is really at risk?</article-title><source>Int Urogynecol J</source><year>2017</year><volume>28</volume><fpage>845</fpage><lpage>850</lpage><pub-id pub-id-type="doi">10.1007/S00192-016-3212-4/TABLES/3</pub-id><pub-id pub-id-type="pmid">27889830</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Miotla P, Cartwright R, Skorupska K, Bogusiewicz M, Markut-Miotla E, Futyma K, et al. Urinary retention in female OAB after intravesical Botox injection: who is really at risk? Int Urogynecol J. 2017;28:845&#x02013;50. 10.1007/S00192-016-3212-4/TABLES/3.<pub-id pub-id-type="pmid">27889830</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Haya</surname><given-names>N</given-names></name><name><surname>Feiner</surname><given-names>B</given-names></name><name><surname>Baessler</surname><given-names>K</given-names></name><name><surname>Christmann-Schmid</surname><given-names>C</given-names></name><name><surname>Maher</surname><given-names>C</given-names></name></person-group><article-title>Perioperative interventions in pelvic organ prolapse surgery</article-title><source>Cochrane Database Syst Rev</source><year>2018</year><volume>8</volume><fpage>CD013105</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD013105</pub-id><pub-id pub-id-type="pmid">30121957</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Haya N, Feiner B, Baessler K, Christmann-Schmid C, Maher C. Perioperative interventions in pelvic organ prolapse surgery. Cochrane Database Syst Rev. 2018;8:CD013105. 10.1002/14651858.CD013105.<pub-id pub-id-type="pmid">30121957</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Maher</surname><given-names>C</given-names></name><name><surname>Feiner</surname><given-names>B</given-names></name><name><surname>Baessler</surname><given-names>K</given-names></name><name><surname>Christmann-Schmid</surname><given-names>C</given-names></name><name><surname>Haya</surname><given-names>N</given-names></name><name><surname>Brown</surname><given-names>J</given-names></name></person-group><article-title>Surgery for women with anterior compartment prolapse</article-title><source>Cochrane Database Syst Rev</source><year>2016</year><volume>11</volume><fpage>CD004014</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD004014.PUB6</pub-id><pub-id pub-id-type="pmid">27901278</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Maher C, Feiner B, Baessler K, Christmann-Schmid C, Haya N, Brown J. Surgery for women with anterior compartment prolapse. Cochrane Database Syst Rev. 2016;11:CD004014. 10.1002/14651858.CD004014.PUB6.<pub-id pub-id-type="pmid">27901278</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Louren&#x000e7;o</surname><given-names>DB</given-names></name><name><surname>Santos</surname><given-names>HOD</given-names></name><name><surname>Hirakawa</surname><given-names>EY</given-names></name><name><surname>Rios</surname><given-names>LAS</given-names></name><name><surname>Lemos</surname><given-names>GC</given-names></name><name><surname>Bianco</surname><given-names>B</given-names></name><etal/></person-group><article-title>Does vaginal surgery for correction of pelvic organ prolapse improve urinary function? A prospective cohort study</article-title><source>Int Urogynecol J</source><year>2024</year><volume>35</volume><fpage>149</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1007/S00192-023-05683-2</pub-id><pub-id pub-id-type="pmid">37999760</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Louren&#x000e7;o DB, Santos HOD, Hirakawa EY, Rios LAS, Lemos GC, Bianco B, et al. Does vaginal surgery for correction of pelvic organ prolapse improve urinary function? A prospective cohort study. Int Urogynecol J. 2024;35:149&#x02013;56. 10.1007/S00192-023-05683-2.<pub-id pub-id-type="pmid">37999760</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Louren&#x000e7;o</surname><given-names>DB</given-names></name><name><surname>Duarte-Santos</surname><given-names>HO</given-names></name><name><surname>Partezani</surname><given-names>AD</given-names></name><name><surname>Teles</surname><given-names>SB</given-names></name><name><surname>Bianco</surname><given-names>B</given-names></name><name><surname>Rios</surname><given-names>LAS</given-names></name><etal/></person-group><article-title>Urodynamic profile of voiding in patients with pelvic organ prolapse after surgery: a systematic review with meta-analysis</article-title><source>Int Urogynecol J</source><year>2023</year><volume>34</volume><fpage>53</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1007/S00192-022-05086-9/METRICS</pub-id><pub-id pub-id-type="pmid">35460345</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Louren&#x000e7;o DB, Duarte-Santos HO, Partezani AD, Teles SB, Bianco B, Rios LAS, et al. Urodynamic profile of voiding in patients with pelvic organ prolapse after surgery: a systematic review with meta-analysis. Int Urogynecol J. 2023;34:53&#x02013;65. 10.1007/S00192-022-05086-9/METRICS.<pub-id pub-id-type="pmid">35460345</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Bazi</surname><given-names>T</given-names></name><name><surname>Kerkhof</surname><given-names>MH</given-names></name><name><surname>Takahashi</surname><given-names>SI</given-names></name><name><surname>Abdel-Fattah</surname><given-names>M</given-names></name></person-group><article-title>Management of post-midurethral sling voiding dysfunction. International Urogynecological Association research and development committee opinion</article-title><source>Int Urogynecol J</source><year>2018</year><volume>29</volume><fpage>23</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1007/S00192-017-3509-Y</pub-id><pub-id pub-id-type="pmid">29170815</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Bazi T, Kerkhof MH, Takahashi SI, Abdel-Fattah M. Management of post-midurethral sling voiding dysfunction. International Urogynecological Association research and development committee opinion. Int Urogynecol J. 2018;29:23&#x02013;8. 10.1007/S00192-017-3509-Y.<pub-id pub-id-type="pmid">29170815</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>AA</given-names></name><name><surname>Tan-Kim</surname><given-names>J</given-names></name><name><surname>Menefee</surname><given-names>SA</given-names></name></person-group><article-title>Long-term risk of reoperation after synthetic mesh midurethral sling surgery for stress urinary incontinence</article-title><source>Obstet Gynecol</source><year>2019</year><volume>134</volume><fpage>1047</fpage><lpage>1055</lpage><pub-id pub-id-type="doi">10.1097/AOG.0000000000003526</pub-id><pub-id pub-id-type="pmid">31599825</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Berger AA, Tan-Kim J, Menefee SA. Long-term risk of reoperation after synthetic mesh midurethral sling surgery for stress urinary incontinence. Obstet Gynecol. 2019;134:1047&#x02013;55. 10.1097/AOG.0000000000003526.<pub-id pub-id-type="pmid">31599825</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Kuo</surname><given-names>HC</given-names></name><name><surname>Liao</surname><given-names>CH</given-names></name><name><surname>Chung</surname><given-names>SD</given-names></name></person-group><article-title>Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome</article-title><source>Eur Urol</source><year>2010</year><volume>58</volume><fpage>919</fpage><lpage>926</lpage><pub-id pub-id-type="doi">10.1016/J.EURURO.2010.09.007</pub-id><pub-id pub-id-type="pmid">20864251</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Kuo HC, Liao CH, Chung SD. Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome. Eur Urol. 2010;58:919&#x02013;26. 10.1016/J.EURURO.2010.09.007.<pub-id pub-id-type="pmid">20864251</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><collab>Writing group of the International Urogynecological Association</collab></person-group><article-title>IUGA report on reporting urodynamics in women</article-title><source>Int Urogynecol J</source><year>2022</year><volume>33</volume><fpage>801</fpage><lpage>807</lpage><pub-id pub-id-type="doi">10.1007/S00192-021-04742-W/FIGURES/1</pub-id><pub-id pub-id-type="pmid">33694003</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Writing group of the International Urogynecological Association. IUGA report on reporting urodynamics in women. Int Urogynecol J 2022;33:801&#x02013;7. 10.1007/S00192-021-04742-W/FIGURES/1.<pub-id pub-id-type="pmid">33694003</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>